Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, January 11, 2024

Technique and impact on first pass effect primary results of the ASSIST global registry

 Survivors don't give a fuck about the intermediate step of reperfusion rates! They want 100% recovery and you bastards are not even measuring that!

“What's measured, improves.” So said management legend and author Peter F. Drucker 

 Technique and impact on first pass effect primary results of the ASSIST global registry

 Rishi Gupta1,

  1. Salvador Miralbés2,
  2. Angel Calleja Bonilla2,
  3. Bharath Naravetla3,
  4. Aniel Q Majjhoo3,
  5. Mahmoud Rayes3,
  6. Alejandro M Spiotta4,
  7. Christian Loehr5,
  8. Andreea Cioltan5,
  9. Dominik F Vollherbst6,
  10. Mario Martínez-Galdámez7,8,
  11. Jorge Galván-Fernandez7,
  12. Ahmad Khaldi1,
  13. Ryan A. McTaggart9,
  14. Mahesh V Jayaraman10,
  15. Luc Defreyne11,
  16. Elisabeth Dhondt11,
  17. Pedro Vega12,
  18. Eduardo Murias12,
  19. Eugene Lin13,
  20. Varun Chaubal13,
  21. Lori Lyn Price14,
  22. David S Liebeskind15,
  23. Markus A Möhlenbruch6
  24. for the ASSIST Investigators
  1. Correspondence to Dr Rishi Gupta, Neurosurgery, WellStar Health System, Marietta, Georgia, USA; guptar31@gmail.com

Abstract

Background Patients treated with mechanical thrombectomy (MT) for acute ischemic strokes from large vessel occlusion (LVO) have better outcomes with effective reperfusion. However, it is unknown which technique leads to better technical and clinical success. We aimed to determine which technique yields the most effective first pass reperfusion during MT.

Methods In a prospective, multicenter global registry we enrolled patients treated with operator preferred MT technique at 71 hospitals from January 2019 to January 2022. Three techniques were assessed: SR Classic with stent retriever (SR) and balloon guide catheter (BGC); SR Combination which employed SR with contact aspiration with or without BGC; and direct aspiration (DA) with or without BGC. The primary outcome was achieving an expanded Thrombolysis In Cerebral Infarction (eTICI) score of 2c or 3 on the first pass, with the primary technique as adjudicated by core lab. The primary clinical outcome measure was a 90-day modified Rankin Scale (mRS) score of 0–2.

Results A total of 1492 patients were enrolled. Patients treated with SR Classic or SR Combination were more likely to achieve first pass eTICI 2c or 3 reperfusion (P=0.01). There was no significant difference in mRS 0–2 (P=0.46) or safety endpoints.

Conclusions The use of SR Classic or SR Combination was more likely to achieve first pass eTICI 2c or 3 reperfusion. There were no significant differences in clinical outcomes and safety endpoints.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

No comments:

Post a Comment